Stock Research for CYCC


Featured Broker: Ally Invest

Get the due diligence for another stock.


CYCC Stock Chart & Research Data

The CYCC chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CYCC chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


CYCC Due diligence Resources & Stock Charts

The CYCC stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View CYCC Detailed Price Forecast - CNN Money CNN View CYCC Detailed Summary - Google Finance
Yahoo View CYCC Detailed Summary - Yahoo! Finance Zacks View CYCC Stock Research & Analysis -

Stock Analysis

TradeIdeas View CYCC Trends & Analysis - Trade-Ideas Barrons View CYCC Major Holders - Barrons
NASDAQ View CYCC Call Transcripts - NASDAQ Seeking View CYCC Breaking News & Analysis - Seeking Alpha
Spotlight View CYCC Annual Report - OTC Report View CYCC OTC Short Report -
TradeKing View CYCC Fundamentals - TradeKing Charts View CYCC SEC Filings - Bar Chart
WSJ View Historical Prices for CYCC - The WSJ Morningstar View Performance/Total Return for CYCC - Morningstar
MarketWatch View the Analyst Estimates for CYCC - MarketWatch CNBC View the Earnings History for CYCC - CNBC
StockMarketWatch View the CYCC Earnings - StockMarketWatch MacroAxis View CYCC Buy or Sell Recommendations - MacroAxis
Bullish View the CYCC Bullish Patterns - American Bulls Short Pains View CYCC Short Pain Metrics -

Social Media Mentions

StockTwits View CYCC Stock Mentions - StockTwits PennyStocks View CYCC Stock Mentions - PennyStockTweets
Twitter View CYCC Stock Mentions - Twitter Invest Hub View CYCC Investment Forum News - Investor Hub
Yahoo View CYCC Stock Mentions - Yahoo! Message Board Seeking Alpha View CYCC Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for CYCC - Insider Cow View Insider Transactions for CYCC - Insider Cow
CNBC View CYCC Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for CYCC - OTC Markets
Yahoo View Insider Transactions for CYCC - Yahoo! Finance NASDAQ View Institutional Holdings for CYCC - NASDAQ

Stock Charts

FinViz View CYCC Stock Insight & Charts - StockCharts View CYCC Investment Charts -
BarChart View CYCC Stock Overview & Charts - BarChart Trading View View CYCC User Generated Charts - Trading View

Latest Financial News for CYCC

What does Cyclacel Pharmaceuticals Inc’s (NASDAQ:CYCC) Balance Sheet Tell Us About Its Future?
Posted on Thursday September 20, 2018

The direct benefit for Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. However, the trade-offRead More...

Cyclacel Pharmaceuticals Appoints Robert J. Spiegel, M.D. to Board of Directors
Posted on Wednesday September 12, 2018

Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer biology, announced the appointment of Robert Spiegel, M.D., FACP, to its Board of Directors. "We are very pleased to have Dr. Robert Spiegel join the Board of Directors of Cyclacel.

Cyclacel Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Trial of Sapacitabine With Olaparib in BRCA Mutant Breast Cancer
Posted on Monday September 10, 2018

Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer biology, announced the initiation of a Phase 1b/2 investigator-sponsored clinical trial to evaluate the safety and effectiveness of sapacitabine in combination with olaparib in patients with BRCA mutant breast cancer. The trial will be conducted at the Dana-Farber Cancer Institute with collaborators Cyclacel and AstraZeneca providing sapacitabine investigational drug and the approved PARP-inhibitor olaparib (LynparzaTM), respectively.

Factors of Influence in 2018, Key Indicators and Opportunity within Aerie Pharmaceuticals, BioScrip, Celsion, Primoris Services, Cyclacel Pharmaceuticals, and Barnes Group — New Research Emphasizes Economic Growth
Posted on Wednesday September 05, 2018

NEW YORK, Sept. 05, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...

Stock Market & Investing Books

Enter a stock symbol to view the stock details.